Welch Group Has Upped Disney Walt Co (DIS) Position; Conatus Pharmaceuticals (CNAT)’s Sentiment Is 0.22

The Walt Disney Company (NYSE:DIS) Logo

Conatus Pharmaceuticals Inc (CNAT) investors sentiment decreased to 0.22 in Q2 2019. It’s down -0.21, from 0.43 in 2019Q1. The ratio dived, as 9 active investment managers opened new and increased holdings, while 21 sold and decreased their stock positions in Conatus Pharmaceuticals Inc. The active investment managers in our database now have: 5.19 million shares, down from 8.29 million shares in 2019Q1. Also, the number of active investment managers holding Conatus Pharmaceuticals Inc in top ten holdings decreased from 1 to 0 for a decrease of 1. Sold All: 7 Reduced: 14 Increased: 5 New Position: 4.

Welch Group Llc increased Disney Walt Co (DIS) stake by 118.87% reported in 2019Q2 SEC filing. Welch Group Llc acquired 4,221 shares as Disney Walt Co (DIS)’s stock rose 4.86%. The Welch Group Llc holds 7,772 shares with $1.09 million value, up from 3,551 last quarter. Disney Walt Co now has $267.51 billion valuation. The stock decreased 0.11% or $0.16 during the last trading session, reaching $148.42. About 3.06M shares traded. The Walt Disney Company (NYSE:DIS) has risen 26.97% since December 4, 2018 and is uptrending. It has outperformed by 26.97% the S&P500. Some Historical DIS News: 29/05/2018 – The Disney-produced “Solo: A Star Wars Story” delivered a franchise-low $83.3 million in North American ticket sales over three days; 26/03/2018 – Non-photo Personalized Gifts Market in the US 2018-2022 with Key Players CafePress, Disney, Hallmark Licensing, Shutterfly and Things Remembered Dominating – ResearchAndMarkets.com; 21/03/2018 – Disney Music Group Set To Release First 6 Remastered Star Wars Original Motion Picture Soundtracks On May 4; 30/05/2018 – JUST IN: President Trump responds to Walt Disney CEO Bob Iger and former Obama aide Valerie Jarrett after Roseanne Barr’s racist tweet leads to the cancellation of the ‘Roseanne’ show; 25/04/2018 – Breitbart News: Report: Disney CEO Bob Iger Aware of John Lasseter’s Alleged Sexual Misconduct Since 2010; 07/05/2018 – Yahoo! UK: Exclusive – Comcast prepares all-cash bid to gate-crash Disney-Fox deal; 08/05/2018 – ♫ Reuters Insider – Exclusive: Comcast readies bid for 21st Century Fox; 02/05/2018 – Casio, Notes For Notes And Disney/Own Star Roshon Fegan Host Special Music Workshop; 08/03/2018 – Disney Shareholders Won’t Endorse CEO Robert Iger’s Compensation Plans; 09/05/2018 – The company’s board has already unanimously approved Disney’s $52 billion offer for those assets

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. The company has market cap of $11.67 million. The Company’s product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. It currently has negative earnings.

More notable recent Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) news were published by: Nasdaq.com which released: “Conatus Pharmaceuticals (CNAT) Reports Q3 Loss, Misses Revenue Estimates – Nasdaq” on November 06, 2019, also Globenewswire.com with their article: “Conatus Pharmaceuticals Appoints Kathy Scott as Independent Board Member – GlobeNewswire” published on November 18, 2019, Globenewswire.com published: “Conatus Pharmaceuticals Reports Third Quarter 2019 Financial Results – GlobeNewswire” on November 05, 2019. More interesting news about Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) were released by: Nasdaq.com and their article: “NASH Scorecard Year to Date: The Winners and the Losers – Nasdaq” published on November 29, 2019 as well as Finance.Yahoo.com‘s news article titled: “Is Conatus Pharmaceuticals Inc.’s (NASDAQ:CNAT) CEO Paid Enough Relative To Peers? – Yahoo Finance” with publication date: November 03, 2019.

A.R.T. Advisors Llc holds 0% of its portfolio in Conatus Pharmaceuticals Inc. for 60,430 shares. Acadian Asset Management Llc owns 467,425 shares or 0% of their US portfolio. Moreover, Albion Financial Group Ut has 0% invested in the company for 12,000 shares. The North Carolina-based Bank Of America Corp De has invested 0% in the stock. Bank Of New York Mellon Corp, a New York-based fund reported 137,500 shares.

Analysts await Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) to report earnings on March, 13. They expect $-0.07 EPS, up 46.15% or $0.06 from last year’s $-0.13 per share. After $-0.10 actual EPS reported by Conatus Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts -30.00% EPS growth.

The stock increased 1.97% or $0.0068 during the last trading session, reaching $0.3518. About 253,033 shares traded. Conatus Pharmaceuticals Inc. (CNAT) has declined 91.73% since December 4, 2018 and is downtrending. It has underperformed by 91.73% the S&P500. Some Historical CNAT News: 04/04/2018 – CONATUS PHARMACEUTICALS INC – THE TRIAL DID NOT MEET ITS PRIMARY ENDPOINT IN HETEROGENEOUS OVERALL TRIAL POPULATION; 04/04/2018 – Conatus Pharmaceuticals: Trial Did Not Meet Its Primary Endpoint in the Heterogeneous Overall Trial Population; 04/04/2018 – CONATUS PHARMACEUTICALS INC – BIOPSY-BASED PROOF OF CONCEPT IN LIVER FIBROSIS AND CIRRHOSIS SUPPORTS FURTHER EVALUATION; 18/04/2018 – Conatus Pharmaceuticals’ IDN-7314 Pan-caspase Inhibitor Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro and In Vivo; 02/05/2018 – Conatus Pharmaceuticals 1Q Loss/Shr 17c; 05/04/2018 – Conatus Closes Below 200-Day Moving Average: Technicals; 10/03/2018 – Conatus Conference Call Scheduled By Seaport for Mar. 14; 04/04/2018 – CONATUS REPORTS TOP-LINE FROM PHASE 2B POLT-HCV-SVR TRIAL; 30/04/2018 – Conatus Announces Completion of Enrollment in ENCORE-PH Phase 2b Clinical Trial of Emricasan in Patients with NASH Cirrhosis an; 04/04/2018 – CONATUS PHARMACEUTICALS INC – ENCORE-NF FOR NASH FIBROSIS TOP-LINE RESULTS EXPECTED IN FIRST HALF OF 2019

Among 13 analysts covering Walt Disney Company (The) Common Stock (NYSE:DIS), 12 have Buy rating, 0 Sell and 1 Hold. Therefore 92% are positive. Walt Disney Company (The) Common Stock has $17500 highest and $130 lowest target. $159.46’s average target is 7.44% above currents $148.42 stock price. Walt Disney Company (The) Common Stock had 21 analyst reports since June 6, 2019 according to SRatingsIntel. The stock of The Walt Disney Company (NYSE:DIS) has “Buy” rating given on Tuesday, November 19 by Rosenblatt. Imperial Capital downgraded it to “In-Line” rating and $14700 target in Monday, June 17 report. Bank of America maintained the stock with “Buy” rating in Monday, June 24 report. The stock of The Walt Disney Company (NYSE:DIS) earned “Buy” rating by J.P. Morgan on Wednesday, October 9. Morgan Stanley maintained The Walt Disney Company (NYSE:DIS) on Thursday, June 13 with “Overweight” rating. As per Wednesday, November 6, the company rating was maintained by UBS. The stock of The Walt Disney Company (NYSE:DIS) has “Overweight” rating given on Thursday, November 14 by JP Morgan. Citigroup maintained the stock with “Buy” rating in Thursday, June 6 report. Imperial Capital maintained the shares of DIS in report on Wednesday, November 20 with “In-Line” rating. Macquarie Research upgraded the stock to “Buy” rating in Wednesday, October 9 report.

Investors sentiment increased to 1.31 in Q2 2019. Its up 0.10, from 1.21 in 2019Q1. It is positive, as 78 investors sold DIS shares while 627 reduced holdings. 195 funds opened positions while 660 raised stakes. 1.17 billion shares or 7.23% more from 1.09 billion shares in 2019Q1 were reported. Hutchinson Capital Ca invested in 2.68% or 68,322 shares. Allsquare Wealth Mngmt Lc invested in 1,358 shares. 119,501 are owned by Private Wealth Prns Limited Liability Corp. Oak Ridge Invests Limited Liability Com has 7,748 shares. Richard C Young & has invested 1.74% in The Walt Disney Company (NYSE:DIS). 40,441 are held by Hyman Charles D. Decatur Capital holds 88,002 shares or 2.31% of its portfolio. Massachusetts Financial Svcs Ma has 0.76% invested in The Walt Disney Company (NYSE:DIS) for 13.29 million shares. Andra Ap holds 38,800 shares. Arrowmark Colorado Holdg Limited Liability Com has 0.01% invested in The Walt Disney Company (NYSE:DIS) for 10,500 shares. Pennsylvania-based First Comml Bank And Tru Of Newtown has invested 0.67% in The Walt Disney Company (NYSE:DIS). Ledyard Retail Bank, a New Hampshire-based fund reported 17,632 shares. Tompkins Finance Corporation holds 39,973 shares or 1.12% of its portfolio. Menora Mivtachim Holdg invested 2.9% of its portfolio in The Walt Disney Company (NYSE:DIS). Forbes J M And Company Limited Liability Partnership has invested 3.38% of its portfolio in The Walt Disney Company (NYSE:DIS).

The Walt Disney Company (NYSE:DIS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.